Page Title
Drug Development Pipeline
Posenacaftor (PTI-801)
Status
DiscontinuedTherapeutic Approach
Restore CFTR Protein
Posenacaftor is a type of CFTR modulator called a corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
Status
Phase 2 studies were conducted to test the safety and effectiveness of posenacaftor alone and in combination with two other CFTR modulators, nesolicaftor (PTI-428) and dirocaftor (PTI-808). No further studies of these compounds are planned at this time.
Sponsor
This program was sponsored by Proteostasis Therapeutics. It was conducted through the Therapeutics Development Network.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More